Table 3.
Compilation of available data on 35 cases of daptomycin-induced eosinophilic pneumonia
| Sex, n (%) | |
| Male | 29 (83) |
| Female | 6 (17) |
| Age(years), mean ± SD | 65.4 ± 15 |
| Daptomycin indication, n (%) | |
| Osteomyelitis/diabetic foot infection | 11 (31) |
| Prosthetic joint infection | 9 (26) |
| Endocarditis | 5 (14) |
| Bacteremia | 4 (11) |
| Abscess | 3 (9) |
| Other | 3 (9) |
| Daptomycin dose (mg/kg/day), mean ± SD | 6.4 ± 1.6 |
| Treatment duration at symptom onset (weeks), mean ± SD | 2.8 ± 1.6 |
| Clinical findings, n (%) | |
| Dyspnea | 33 (94) |
| Fever | 20 (57) |
| Cough | 13 (37) |
| Requiring oxygen | 15 (43) |
| Requiring mechanical ventilation | 12 (34) |
| Infiltrates/opacities of CT/CXR, n (%) | 30 (86) |
| BAL eosinophils %, mean ± SD | 32 ± 22.4 |
| Peripheral eosinophilia, n (%) | 27 (77) |
| Lung biopsy consistent with AEP, n (%) | 6 (17) |
| Treatment, n (%) | |
| Daptomycin discontinued only | 12 (34) |
| Daptomycin discontinued plus corticosteroid | 23 (66) |
AEP acute eosinophilic pneumonia, BAL bronchoalveolar lavage, CT computed tomography, CXR chest x-ray, SD standard deviation